» Articles » PMID: 17521585

Ectopic Lymphoid-organ Development Occurs Through Interleukin 7-mediated Enhanced Survival of Lymphoid-tissue-inducer Cells

Overview
Journal Immunity
Publisher Cell Press
Date 2007 May 25
PMID 17521585
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Development of Peyer's patches and lymph nodes requires the interaction between CD4+ CD3- IL-7Ralpha+ lymphoid-tissue inducer (LTi) and VCAM-1+ organizer cells. Here we showed that by promoting their survival, enhanced expression of interleukin-7 (IL-7) in transgenic mice resulted in accumulation of LTi cells. With increased IL-7 availability, de novo formation of VCAM-1+ Peyer's patch anlagen occurred along the entire fetal gut resulting in a 5-fold increase in Peyer's patch numbers. IL-7 overexpression also led to formation of multiple organized ectopic lymph nodes and cecal patches. After immunization, ectopic lymph nodes developed normal T cell-dependent B cell responses and germinal centers. Mice overexpressing IL-7 but lacking either RORgamma, a factor required for LTi cell generation, or lymphotoxin alpha1beta2 had neither Peyer's patches nor ectopic lymph nodes. Therefore, by controlling LTi cell numbers, IL-7 can regulate the formation of both normal and ectopic lymphoid organs.

Citing Articles

Spatial characterization of tertiary lymphoid structures as predictive biomarkers for immune checkpoint blockade in head and neck squamous cell carcinoma.

Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T Oncoimmunology. 2025; 14(1):2466308.

PMID: 39963988 PMC: 11845054. DOI: 10.1080/2162402X.2025.2466308.


IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.

Amisaki M, Zebboudj A, Yano H, Zhang S, Payne G, Chandra A Nature. 2025; 638(8052):1076-1084.

PMID: 39814891 PMC: 11864983. DOI: 10.1038/s41586-024-08426-5.


Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer.

Ruiz-Torres D, Bryan M, Hirayama S, Merkin R, Luciani E, Roberts T medRxiv. 2024; .

PMID: 39314968 PMC: 11419212. DOI: 10.1101/2024.09.10.24313432.


Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.

Zhao L, Jin S, Wang S, Zhang Z, Wang X, Chen Z Signal Transduct Target Ther. 2024; 9(1):225.

PMID: 39198425 PMC: 11358547. DOI: 10.1038/s41392-024-01947-5.


Exploiting tertiary lymphoid structures gene signature to evaluate tumor microenvironment infiltration and immunotherapy response in colorectal cancer.

Xu Z, Wang Q, Zhang Y, Li X, Wang M, Zhang Y Front Oncol. 2024; 14:1383096.

PMID: 38846981 PMC: 11153738. DOI: 10.3389/fonc.2024.1383096.